Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP: RHHBY )

41.05 USD +0.08 (+0.20%)
Official Closing Price Updated: 4:42 PM EST, Mar 2, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,383,600
Open 41.19
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 40.97
Today's Range 40.95 - 41.35
52wk Range 35.04 - 47.15
Shares Outstanding 6,830,797,784
Dividend Yield 2.24%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Spark Therapeutics Further Strengthens Technical Expertise with Appointment of Cynthia Pussinen as Chief Technical Officer
From GlobeNewswire News Releases
Atea Pharmaceuticals Announces Chugai In-License of AT-527 from Roche for the Treatment of COVID-19 in Japan
Chugai obtains exclusive development and marketing rights for AT-527 in Japan from Roche, who has ex-US rights for the treatment of COVID-19 
From GlobeNewswire News Releases

Performance

YTD
-6.45%
-6.45%
1 Month
-5.63%
-5.63%
3 Month
-1.63%
-1.63%
6 Month
-7.75%
-7.75%
1 Year
-0.36%
-0.36%

More News

Read More
Genentech Announces Results From Evrysdi (risdiplam) Study in Infants With Type 1 Spinal Muscular Atrophy (SMA) Published in New England Journal of Medicine
From Business Wire News Releases
OTC Markets Group On The Importance Of Investor Relations During A Pandemic
Tags RHHVF GPDNF BNPQY
From Benzinga
Regeneron's COVID-19 Antibody Cocktail Wins EU Positive Opinion
Tags RHHVF REGN CHMP
From Benzinga
Roche Reports Positive Evrysdi Data From Dose-Finding Part Of Spinal Muscular Atrophy Trial
Tags Biotech Spinal Muscular Atrophy Market News
From Benzinga
Opthea Outlines OPT-302 Pivotal Study Designs In Chronic Eye Disorder
Tags Benzinga Age/Related Macular Degeneration News
From Benzinga
New Phase III Data Show Genentech’s Faricimab Is the First Investigational Injectable Eye Medicine to Extend Time Between Treatments up to Four Months in Two Leading Causes of Vision Loss, Potentially
From Business Wire News Releases
Why Turning Point Is Turning Heads
Tags TPTX Market News AMGN
From Motley Fool
2 Best Pharma Stocks to Buy Right Now
Tags AMGN BIIB MYL
From Motley Fool
Roche's Faricimab On Par With Rival Regeneron's Aflibercept In Four Late-Stage Studies In Vision Loss Disorder
Tags Phase 3 Trial RHHBY Biotech
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.